DiscGenics to use MedCision's ThawSTAR system for cell therapy trial: 4 notes

Biologics

DiscGenics will participate in MedCision's ThawSTAR Early Adopter Program.

Here are four notes:

 

1. The ThawSTAR Early Adopter Program is designed to assist companies "de-risk thawing of frozen cell therapies in early stage clinical trials through to commercialization and point-of-care."

 

2. DiscGenics' therapy candidate, IDCT, is intended for degenerative disc disease patients. The company will use the ThawSTAR technology in its U.S. clinical trial of IDCT for DDD.

 

3. The ThawSTAR CFT2 System is an automated cell thawing system that helps limit cell handling risk and variability.

 

4. The ThawSTAR leverages a customized algorithm for IDCT, noting cell size, volume and cryopreservative choice. This customization will allow for the cell-based therapy's optimal performance.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers